Tag Archives: DEPO

Depomed (DEPO) SVP Matthew M. Gosling Sells 19,674 Shares

Depomed (NASDAQ:DEPO) SVP Matthew M. Gosling sold 19,674 shares of the business’s stock in a transaction on Friday, May 11th. The shares were sold at an average price of $7.07, for a total transaction of $139,095.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Matthew M. Gosling also recently made the following trade(s):

Get Depomed alerts:

On Wednesday, March 7th, Matthew M. Gosling sold 45,519 shares of Depomed stock. The shares were sold at an average price of $6.58, for a total transaction of $299,515.02.

Depomed opened at $7.58 on Friday, Marketbeat Ratings reports. The company has a quick ratio of 0.73, a current ratio of 0.75 and a debt-to-equity ratio of 2.55. The firm has a market cap of $478.18 million, a price-to-earnings ratio of -6.02 and a beta of 1.22. Depomed has a fifty-two week low of $7.43 and a fifty-two week high of $7.53.

Depomed (NASDAQ:DEPO) last posted its quarterly earnings data on Thursday, May 10th. The specialty pharmaceutical company reported $0.28 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.69. The company had revenue of $128.40 million during the quarter, compared to analysts’ expectations of $65.77 million. Depomed had a negative net margin of 10.02% and a negative return on equity of 15.74%. The firm’s revenue for the quarter was up 41.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.07 earnings per share. equities research analysts predict that Depomed will post -1.1 EPS for the current year.

Several research firms recently issued reports on DEPO. Piper Jaffray reiterated a “hold” rating and issued a $8.00 target price on shares of Depomed in a research note on Thursday, March 1st. BidaskClub upgraded shares of Depomed from a “sell” rating to a “hold” rating in a research report on Wednesday, February 21st. Roth Capital set a $10.00 price objective on shares of Depomed and gave the stock a “buy” rating in a research report on Friday, March 2nd. ValuEngine cut shares of Depomed from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Mizuho restated a “buy” rating and set a $9.00 price objective on shares of Depomed in a research report on Friday, March 23rd. Two analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $8.00.

Large investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in shares of Depomed in the fourth quarter valued at about $127,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Depomed in the fourth quarter valued at about $131,000. ClariVest Asset Management LLC acquired a new stake in shares of Depomed in the first quarter valued at about $108,000. MANA Advisors LLC acquired a new stake in shares of Depomed in the fourth quarter valued at about $148,000. Finally, Teacher Retirement System of Texas acquired a new stake in shares of Depomed in the fourth quarter valued at about $155,000. Institutional investors own 94.38% of the company’s stock.

Depomed Company Profile

Depomed, Inc, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults.

Top Blue Chip Stocks To Invest In Right Now

Over the past year, the performance of T. Rowe Price Blue Chip Growth (TRBCX has underscored why it pays to sit tight when a fund with a superior long-term record hits a speed bump. In 2016, as investors turned away from shares of the fast-growing, large-capitalization stocks that Blue Chip targets in favor of more-undervalued fare, the fund lagged the stock market dramatically. Stocks that had previously buoyed the fund, such as Amazon.com and Facebook, were suddenly a drag, says manager Larry Puglia. And energy and utility stockssectors that Blue Chip tends to ignoreperformed exceptionally well.

See Also: Kip 25 Best No-Load Mutual Funds 2017

But these kinds of style shifts dont last forever. Large-cap growth stocks, led by the technology sector, are rebounding this year, and Blue Chip is benefiting. In the first three months of 2017, the fund returned 10.4%, beating Standard & Poors 500-stock index by 4.3 percentage points. Over the past 12 months, Blue Chip, a member of the Kiplinger 25, outpaced the index by nearly a full percentage point. (Prices and returns are through March 31)

Top Blue Chip Stocks To Invest In Right Now: Cerner Corporation(CERN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Cerner (CERN) soared to the top of the S&P 500 today after thehealth care information technology company reported better-than-expected earnings and revenue.

    Getty Images

    Cernergained 7.8% to $64.75 at 5:03 p.m. today, while the S&P 500 declined 0.2% to 2,384.20.

    Canaccord Genuity’s Richard Close and Brian Hoffman contend Cerner may be “rediscovered its mojo.” They explain:

    We reiterate our BUY rating and raise our PT to $66 (was $59) as the company finally
    appears to have provided quarterly and annual targets that it can meet. Possibly more important, analyst expectations sit near the mid-point of guidance, portending upside potential. The outlook appears solid as the company (1) rebuilds a track record of delivering on expectations, (2) reaffirmed confidence in 2017 bookings growth, and (3) has a strengthened pipeline for ITWorks and revenue cycle. CERN may have rediscovered its mojo.

    Cerner’s market capitalization rose to $21.4 billion today from $19.8 billion yesterday.

  • [By ]

    Cerner Corp (Nasdaq: CERN) is the largest pure-play health care IT (HCIT) company in the world with clients in 30 countries and a footprint at 70 of the top 100 global health systems by patient revenue. The company is the market leader in health systems outside the United States with 28% of an otherwise fragmented market.

  • [By Ben Levisohn]

    Cerner (CERN) tumbled to the bottom of the S&P 500 today after meetings earnings forecasts but offering below-consensus guidance.

    Agence France-Presse/Getty Images

    Cerner dropped 4.4% to $51.50 today, while the S&P 500 rose 0.4% to 2,316.10.

    SunTrust Robinson Humphrey’s Sandy Draper and team contend that “most of the bad news is already priced in.” They explain:

    Although we expect this news to weigh on the stock…we think the market has remained cautious on CERN shares heading into the 4Q16 print given the uneven execution throughout 2016 and the post-election regulatory uncertainty that has broadly weighed on the HCIT space as a whole. We observe that CERN shares closed about 3% below the level they traded at this time last year, while the S&P was up over 21% in that time. The muted 12-month performance in the stock suggests the market rightly anticipated unattractive year-end results and 2017 guidance, which suggests to us that downside to CERN shares should be limited.

    Cerner’s market capitalization fell to $17.5 billion today from $18.3 billion yesterday.

    Barron’s Vito Racanelli recommended shares of Cerner on March 16, 2016, when the stock traded at $51.46.

Top Blue Chip Stocks To Invest In Right Now: DepoMed Inc.(DEPO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Depomed Inc (NASDAQ: DEPO) got a boost, shooting up 13 percent to $23.90. Depomed is preparing to put itself up for sale, following calls from activist investor Starboard Value LP to explore such a move, just a year after it fought off a hostile acquisition bid, people familiar with the matter told Reuters.

Top Blue Chip Stocks To Invest In Right Now: EnLink Midstream Partners, LP(ENLK)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    EnLink Midstream Partners (ENLK) is sponsored by independent oil and gas exploration giant Devon Energy (DVN), the owner of this acreage.

    These basins offer superior economics and EnLink’s close relationship with Devon provides leveraged exposure to the upstream operator’s accelerating activity in these plays.

Top Blue Chip Stocks To Invest In Right Now: Frontline Ltd.(FRO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Wednesday afternoon, the energy shares surged 1.23 percent. Meanwhile, top gainers in the sector included Frontline Ltd. (NYSE: FRO), up 5 percent, and JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO), up 6 percent.

  • [By Rich Smith]

    So what is it that’s supporting DHT’s stock price in the face of sliding shipping rates for crude oil, retreating revenue, and plunging profits? Well, for one thing, rival tanker companyFrontline (NYSE:FRO) made an unsolicited bid to acquire DHT last week, offering to pay $475 million for the company. (DHT is currently valued at $460 million.)

  • [By Shanthi Rexaline]

    Frontline Ltd. (NYSE: FRO) is projected to post a loss in the second quarter, translating to a zero dividend, Credit Suisse said in a Tuesday note. Notwithstanding the negative opinion, the shares of the company were up in reaction to the possibility of a deal being struck.

Top Blue Chip Stocks To Invest In Right Now: Protective Life Corporation(PL)

Advisors’ Opinion:

  • [By David Sterman]

    My favorite insurers: AIG (NYSE: AIG) (which I discussed a few months ago), Protective Life (NYSE: PL) and Reinsurance Group of America (NYSE: RGA).

30 Stocks Moving In Tuesday's Mid-Day Session

Revance Therapeutics, Inc. (NASDAQ: RVNC) shares jumped 33.7 percent to $34.75 after the company disclosed that its RT002 met primary and all secondary endpoints.
Barnes & Noble Education, Inc. (NYSE: BNED) shares climbed 21.5 percent to $7.6200 after the company reported Q2 results.
Moleculin Biotech, Inc. (NASDAQ: MBRX) shares gained 18.9 percent to $2.1631 after the company disclosed that its WP1066 drug has received the FDA brain tumor IND clearance.
Depomed, Inc. (NASDAQ: DEPO) shares gained 14.75 percent to $8.2052 after the company disclosed NUCYNTA® Commercialization Agreement with Collegium Pharmaceutical.
G-III Apparel Group, Ltd. (NASDAQ: GIII) jumped 13.9 percent to $34.32 on better-than-expected quarterly earnings.
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) gained 10.9 percent to $18.78. Depomed, Inc. (NASDAQ: DEPO) disclosed a NUCYNTA® Commercialization Agreement with Collegium Pharmaceutical.
Digital Ally, Inc. (NASDAQ: DGLY) shares rose 10 percent to $2.7498. The U.S. Patent Office will issue Digital Ally a patent next week for the firm’s wirelessly conducted electroshock weapon, according to a Tuesday press release.
Akari Therapeutics, Plc (NASDAQ: AKTX) gained 10 percent to $5.289.
J.Jill, Inc. (NYSE: JILL) shares rose 9.4 percent to $7.0573 following Q3 results.
Regal Entertainment Group (NYSE: RGC) surged 9.1 percent to $22.61 after the company agreed to be acquired by Cineworld Group PLC.
Lands' End, Inc. (NASDAQ: LE) shares rose 8.9 percent to $12.85 following Q3 results.
Snap Inc. (NYSE: SNAP) gained 7.8 percent to $14.64. Barclays upgraded Snap from Equal-Weight to Overweight.
HD Supply Holdings, Inc. (NASDAQ: HDS) gained 7 percent to $39.0500 after reporting better-than-expected quarterly results.
AutoZone, Inc. (NYSE: AZO) rose 3 percent to $730.44 on upbeat quarterly earnings.

Losers
Galectin Therapeutics, Inc. (NASDAQ: GALT) dipped 45.64 percent to $1.3481 as the company reported that its Phase 2b NASH-CX trial did not meet its primary endpoint.
Wins Finance Holdings Inc. (NASDAQ: WINS) shares fell 30.7 percent to $58.88 after dropping 58.54 percent on Monday.
Ascena Retail Group, Inc. (NASDAQ: ASNA) fell 20.5 percent to $2.075. Ascena Retail reported in-line earnings for its first quarter. The company reported a 5 percent drop in its Q1 comps and issued weak second quarter guidance.
EMCORE Corporation (NASDAQ: EMKR) dropped 19 percent to $6.00 following Q4 results.
Astrotech Corporation (NASDAQ: ASTC) shares declined 18.5 percent to $3.78. Astrotech shares surged 69.34 percent Monday after the company reported that it has completed its successful 1st Detect demo with with Department of Homeland Security and Transportation Security Administration personnel.
NextDecade Corporation (NASDAQ: NEXT) shares fell 15.76 percent to close at $8.02.
Helios and Matheson Analytics Inc. (NASDAQ: HMNY) shares dropped 14.2 percent to $10.32 after slipping 0.25 percent on Monday.
Tabula Rasa Healthcare, Inc. (NYSE: TRHC) shares slipped 10.90 percent to $29.09.
MER Telemanagement Solutions Ltd. (NASDAQ: MTSL) fell 10.5 percent to $1.88.
Francesca's Holdings Corporation (NASDAQ: FRAN) shares declined 10.1 percent to $7.01 following downbeat quarterly earnings.
SIFCO Industries, Inc. (NYSE: SIF) shares fell 10 percent to $7.00.
Heron Therapeutics, Inc. (NASDAQ: HRTX) shares declined 9.8 percent to $15.475 after announcing public offering of common stock
Edison International (NYSE: EIX) fell 8.6 percent to $73.36.
Digital Power Corporation (NYSE: DPW) dropped 7.7 percent to $3.2201 following news of offering by selling shareholders. The stock ran up more than 90 percent in the regular session.
Toll Brothers, Inc. (NYSE: TOL) shares fell 7.6 percent to $46.795, after reporting downbeat quarterly results.
Social Reality, Inc. (NASDAQ: SRAX) shares dropped 7.4 percent to $5.1657.

stock shares

Facebook (NASDAQ:FB) does not report its calendar Q4 ’16 quarter and financial results until February 1, 2017, but investors have been nervous about the stock since – with the post-presidential election rally in the 4th quarter of 2016 – Facebook actually fell 10% for the three months that ended 2016, even as the rest of the market rallied nicely.

A big part of that 10% decline was due to the first pass at 2017 guidance by Facebook’s management on the 3rd quarter 2016 conference call last November 2nd, 2016, where Facebook cautioned that 2017 revenue would be impacted by ad load factors and 2017 expenses might be higher too.

Also guiding cautiously for a tough Q4 ’16, Facebook said that:

Revenue growth rates would decline due to tough comps. Expense guidance would be at the low end of the 30%-35% range. Revenue and “other fees” payments would be lower in Q4 ’16.

Facebook also said that “official” 2017 guidance would be given on the February 2017 call.

But here is the thing:

stock shares: Credit Acceptance Corporation(CACC)

Advisors’ Opinion:

  • [By Wayne Duggan]

    Credit Acceptance Corp. (NASDAQ: CACC) shares are down more than 5.1 percent on Friday after Bloomberg reported that the Federal Trade Commission has requested information from the company regarding its use of ignition kill switches and GPS systems in debt collection.

stock shares: Discovery Communications, Inc.(DISCA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

    Analysts are expecting Discovery Communications Inc. (NASDAQ: DISCA) to have earned $0.47 per share on revenue of $1.69 billion in the latest quarter. Discovery Communications shares rose 0.17 percent to $29.08 in after-hours trading.
    Analysts expect T-Mobile US Inc (NASDAQ: TMUS) to report

  • [By Lisa Levin]

    Discovery Communications Inc. (NASDAQ: DISCA) announced plans to acquire Scripps Networks Interactive, Inc. (NYSE: SNI) for $14.6 billion.

    Discovery will pay $90 per share in cash and stock to buy Scripps. The transaction is projected to close by early 2018.

stock shares: Black Box Corporation(BBOX)

Advisors’ Opinion:

  • [By Monica Gerson]

    Black Box Corporation (NASDAQ: BBOX) is expected to post its quarterly earnings at $0.26 per share on revenue of $218.41 million.

    Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

stock shares: DepoMed Inc.(DEPO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Depomed Inc (NASDAQ: DEPO) got a boost, shooting up 13 percent to $23.90. Depomed is preparing to put itself up for sale, following calls from activist investor Starboard Value LP to explore such a move, just a year after it fought off a hostile acquisition bid, people familiar with the matter told Reuters.

Best Value Stocks To Own For 2018

Geopolitical risk always exists. But historically, from an investing standpoint, it hasn’t mattered.

Each month, we book time with some of our company’s top financial brain power to answer questions about investing and your finances. This month we’re talking about political risk and your investments.

Our financial experts:

Ron Joelson is Northwestern Mutual’s chief investment officer and oversees the company’s general account, valued at approximately $200 billion as of June of 2016.

Mark McLennon is vice president of Investment Products and Services (IPS) Business Development. He oversees the fee-based financial planning program and departmental growth initiatives.

Best Value Stocks To Own For 2018: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Position: Long GLD small, bonds, SDS; short TLT small, SPY small .

  • [By WWW.THESTREET.COM]

    Celgene (CELG) : “Celgene’s a buy, I think it’s terrific.”

    Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

  • [By Peter Graham]

    A long term performance shows shares of small cap cancer stocks Juno Therapeutics and Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) underperforming whileKite Pharma Inc (NASDAQ: KITE)andlarge cap Celgene Corporation (NASDAQ: CELG) have performed better:

Best Value Stocks To Own For 2018: Wayfair Inc.(W)

Advisors’ Opinion:

  • [By Peter Graham]

    Mid cap online home furnishings and d茅cor stockWayfair Inc (NYSE: W) reported Q1 earnings before the market opened with the Company being thetenth most shorted stock on the NYSE with short interest of 39.22% according to Highshortinterest.com. In the summer of 2008,the shorts and shareholder rights law firms went after Wayfair Inc after short seller Citron Research issued a report (entitled: Wayfair is the Most Mispriced Stock Citron Research has Seen in Years: Fair Value Under $10) calling the company Overstock.com, Inc (NASDAQ: OSTK):

  • [By Peter Graham]

    The Q4 2016 earnings report formid cap online home furnishings and d茅cor stockWayfair Inc (NYSE: W) is scheduled for before the market opens onThursday (February 23rd) as shares still have elevated short interest of 34.99% according to Highshortinterest.com. Last time around, shares dropped as much as 13%after the Company reported third quarter revenues and net losses that largely met expectations while projecting aslight decrease in revenue growth for the coming quarter.

  • [By Lisa Levin]

    Wayfair Inc (NYSE: W) shares were also up, gaining 25 percent to $63.71 after first-quarter earnings boasted a 2.7-percent sales beat and 46-percent year-over-year increase in active customers.

Best Value Stocks To Own For 2018: Medidata Solutions, Inc.(MDSO)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Wednesday, technology shares climbed by 0.94 percent. Top gainers in the sector included Marvell Technology Group Ltd. (NASDAQ: MRVL) and Medidata Solutions Inc (NASDAQ: MDSO).

  • [By Peter Graham]

    A long term performance chart shows shares of Veeva Systems outperformingunderperforming small cap peerModel N Inc (NYSE: MODN) while mid cap Medidata Solutions (NASDAQ: MDSO) has been a huge outperformer that has just moved past its 2014 peak:

Best Value Stocks To Own For 2018: DepoMed Inc.(DEPO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Depomed Inc (NASDAQ: DEPO) got a boost, shooting up 13 percent to $23.90. Depomed is preparing to put itself up for sale, following calls from activist investor Starboard Value LP to explore such a move, just a year after it fought off a hostile acquisition bid, people familiar with the matter told Reuters.

Best Value Stocks To Own For 2018: MarketAxess Holdings, Inc.(MKTX)

Advisors’ Opinion:

  • [By ]

    This is why I’m bullish on a company that promises to mitigate the liquidity issues facing the bond market. The company is MarketAxess (Nasdaq: MKTX).

  • [By Joe Tenebruso]

    MarketAxessHoldings (NASDAQ:MKTX)reported first-quarter results on April 26. The electronic trading platform is enjoying strong gains in revenue and profits as it continues to take share of the massive global fixed-income market.